Cell-based advanced therapy medicinal products (ATMPs) such as CAR T, CAR NK, TIL and TCR T therapies represent an emerging form of cancer treatment wherein engineered immune cells form the basis of the therapy.​ However, the complex techniques needed to generate ATMPs, and the biological demands to make them effective for various cancer types, present many challenges.

Led by pioneers in the field of cell and gene therapy, the Oncode Accelerator Cell and Gene Therapy Workstream combines topnotch scientific experience with a multidisciplinary academic infrastructure to build and optimize robust preclinical pipelines for ATMP development.

Watch the recording here of this expert-led webinar, which took place on October 7th, 2025 and begin to tap into their extensive scientific expertise, and learn how you can leverage Oncode Accelerator’s innovative infrastructure and plug-and-play production modules for the development of oncological cell and gene therapies.